{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CAPS-IV", "query": { "intervention": "CAPS-IV" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 518, "total_pages": 52, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CAPS-IV&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-11T22:24:58.243Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04082364", "title": "Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Gastric Cancer", "Gastroesophageal Junction Cancer", "HER2-positive Gastric Cancer" ], "interventions": [ { "name": "margetuximab", "type": "BIOLOGICAL" }, { "name": "Retifanlimab", "type": "BIOLOGICAL" }, { "name": "Tebotelimab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Chemotherapy", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 82, "start_date": "2019-09-30", "completion_date": "2025-03-25", "has_results": true, "last_update_posted_date": "2025-06-08", "last_synced_at": "2026-09-11T22:24:58.243Z", "location_count": 28, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 25 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Salinas", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04082364" }, { "nct_id": "NCT01589068", "title": "Effects of Progesterone on IV Nicotine Induced Changes on BOLD fMRI Signal, Hormones and Subjective Ratings of Stimulant Drugs", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Nicotine Dependence" ], "interventions": [ { "name": "Intravenous Nicotine", "type": "DRUG" }, { "name": "Progesterone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mclean Hospital", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 0, "start_date": "2007-01", "completion_date": "2015-12-01", "has_results": false, "last_update_posted_date": "2024-01-17", "last_synced_at": "2026-09-11T22:24:58.243Z", "location_count": 1, "location_summary": "Belmont, Massachusetts", "locations": [ { "city": "Belmont", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01589068" }, { "nct_id": "NCT04191096", "title": "Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Hormone-Sensitive Prostate Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Androgen Deprivation Therapy (ADT)", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 1251, "start_date": "2020-02-12", "completion_date": "2026-04-08", "has_results": true, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-09-11T22:24:58.243Z", "location_count": 27, "location_summary": "Anchorage, Alaska • Duarte, California • Los Angeles, California + 22 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04191096" }, { "nct_id": "NCT06906341", "title": "Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Peritoneal Neoplasms", "Endometrial Cancer" ], "interventions": [ { "name": "Relacorilant 150 mg once daily (QD)", "type": "DRUG" }, { "name": "Nab-paclitaxel 80 mg/m^2", "type": "DRUG" }, { "name": "Bevacizumab 10 mg/kg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Corcept Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 270, "start_date": "2025-04-11", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-09-11T22:24:58.243Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Palo Alto, California • San Francisco, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06906341" }, { "nct_id": "NCT03833427", "title": "Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced/Metastatic Solid Tumors" ], "interventions": [ { "name": "Selumetinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2019-03-18", "completion_date": "2022-06-28", "has_results": true, "last_update_posted_date": "2024-11-07", "last_synced_at": "2026-09-11T22:24:58.243Z", "location_count": 4, "location_summary": "Duarte, California • Grand Rapids, Michigan • Hackensack, New Jersey + 1 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03833427" }, { "nct_id": "NCT03016312", "title": "A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms, Castration-Resistant" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 759, "start_date": "2017-01-10", "completion_date": "2022-12-20", "has_results": true, "last_update_posted_date": "2024-08-09", "last_synced_at": "2026-09-11T22:24:58.243Z", "location_count": 39, "location_summary": "Duarte, California • La Jolla, California • Los Angeles, California + 33 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03016312" }, { "nct_id": "NCT03752307", "title": "Safety and Tolerability of ISX (Isoxsuprine HCL) in MS Relapses", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Isoxsuprine Hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Corticosteroid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of New Mexico", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 2, "start_date": "2019-02-15", "completion_date": "2023-07-06", "has_results": true, "last_update_posted_date": "2024-02-06", "last_synced_at": "2026-09-11T22:24:58.243Z", "location_count": 1, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT03752307" }, { "nct_id": "NCT03048344", "title": "A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Hematological Disorders" ], "interventions": [ { "name": "ORH-2014", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Orsenix LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2016-12-02", "completion_date": "2019-02-28", "has_results": false, "last_update_posted_date": "2019-03-25", "last_synced_at": "2026-09-11T22:24:58.243Z", "location_count": 4, "location_summary": "New York, New York • Nashville, Tennessee • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03048344" }, { "nct_id": "NCT00003850", "title": "Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "1999-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-08", "last_synced_at": "2026-09-11T22:24:58.243Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003850" }, { "nct_id": "NCT01265849", "title": "Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Squamous Cell Carcinoma of the Oral Cavity", "Squamous Cell Carcinoma of the Soft Palate" ], "interventions": [ { "name": "LI", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Indomethacin", "type": "DRUG" }, { "name": "Zinc", "type": "DIETARY_SUPPLEMENT" }, { "name": "Surgery", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DIETARY_SUPPLEMENT", "PROCEDURE", "RADIATION" ], "sponsor": "CEL-SCI Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 928, "start_date": "2010-12", "completion_date": "2020-12-04", "has_results": true, "last_update_posted_date": "2022-08-19", "last_synced_at": "2026-09-11T22:24:58.243Z", "location_count": 5, "location_summary": "Springfield, Illinois • Detroit, Michigan • Cincinnati, Ohio + 2 more", "locations": [ { "city": "Springfield", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01265849" } ] }